Posted by Michael Wonder on 25 Apr 2019
No outcomes on breast cancer drugs Kadcyla and Ibrance yet, says PHARMAC
24 April 2019 - PHARMAC has reiterated that it has not yet made a decision on whether to fund two breast cancer drugs, after a press release from a support group for women with breast cancer said it had refused an application for funding.
The Breast Cancer Aotearoa Coalition yesterday said PHARMAC had refused funding for Kadcyla, one of two drugs which women with advanced breast cancer hope will be funded by PHARMAC.
"This is a huge blow for women with advanced HER2 positive breast cancer who took a petition to Parliament in October 2018 calling for PHARMAC to fund this medicine," Breast Cancer Aotearoa chairwoman Libby Burgess said in a statement.
